The process of investigating a possible cure for coronavirus disease 2019 (COVID-19) in vitro and in vivo may take a long time. For this reason, several in silico studies were performed in order to produce preliminary results that could lead to treatment. Extract of Juniperus procera Hochst is used as a traditional medicine for recovery from flu in Saudi Arabia. In the present study, more than 51 phytochemicals of J. procera were docked against the main protease of COVID-19. Rutin gave the highest interaction score among all the phytochemicals and the commercially available antiviral drugs. Lopinavir showed the second highest binding score. Rutin and lopinavir were further investigated using homology models of COVID-19. Rutin showed a better inhibition score in 9 of the 11 of homology models compared with lopinavir. Analysis of ligand-protein interaction contacts revealed that 3 residues (Glu166, Gly143, and Thr45) of the main protease formed hydrogen bonds with rutin. This simulation study suggests that rutin could be a possible effective inhibitor of several COVID-19 protein targets, including the main protease. Rutin, already available for commercial use, was evaluated for its ability as a possible drug. To our knowledge, this is the first study that suggests rutin having a possible strong inhibitory role against several protein targets of COVID-19.

在体内外研究研究冠状病毒病2019（COVID-19）的可能治愈方法的过程可能需要很长时间。因此，进行了一些计算机模拟研究，以产生可能导致治疗的初步结果。刺柏的提取物被用作从沙特阿拉伯的流感中恢复的传统药物。在本研究中，超过51种的植物化学物质J.的Procera与COVID-19的主要蛋白酶对接。芦丁在所有植物化学药品和市售抗病毒药物中的相互作用评分最高。Lopinavir表现出第二高的结合得分。使用COVID-19的同源性模型进一步研究了芦丁和洛匹那韦。与洛匹那韦相比，芦丁在11个同源模型中的9个中显示出更好的抑制评分。配体-蛋白质相互作用接触的分析表明，主要蛋白酶的3个残基（Glu166，Gly143和Thr45）与芦丁形成氢键。这项模拟研究表明，芦丁可能是几种COVID-19蛋白靶标（包括主要蛋白酶）的有效抑制剂。已对可用于商业用途的芦丁进行了评估，以作为可能药物的能力。据我们所知，